Diphtheria-tetanus-inactivated poliovirus vaccine - sanofi pasteur

Drug Profile

Diphtheria-tetanus-inactivated poliovirus vaccine - sanofi pasteur

Alternative Names: REVAXIS; Td-eIPV

Latest Information Update: 26 Mar 2015

Price : $50

At a glance

  • Originator sanofi pasteur
  • Developer Sanofi Pasteur
  • Class Bacterial vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Poliomyelitis; Tetanus

Most Recent Events

  • 18 Jan 2005 Aventis Pasteur is now called sanofi pasteur
  • 29 Oct 2004 Launched for Diphtheria in United Kingdom (IM)
  • 29 Oct 2004 Launched for Poliomyelitis in United Kingdom (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top